Cowden Syndrome

Cowden syndrome (CS) is a rare inherited condition caused by a mutation in the PTEN gene, which normally helps control cell growth. The hallmark of the disease is the development of multiple benign (non-cancerous) growths — called hamartomas — on the skin, mucous membranes, and internal organs. More importantly, Cowden syndrome significantly increases the lifetime risk of developing certain cancers, particularly of the breast, thyroid, and uterus. Cowden syndrome belongs to a group of conditions collectively known as PTEN hamartoma tumor syndrome (PHTS).

Cowden syndrome is rare, but likely underdiagnosed because its signs can be subtle and develop gradually.

• Prevalence: Approximately 1 in 200,000 people
• Inheritance: Autosomal dominant — a single copy of the altered gene inherited from one parent is sufficient to cause the condition; each child of an affected parent has a 50% chance of inheriting it
• Age of onset: Mucocutaneous (skin and mucous membrane) lesions typically appear in the late teens to twenties; cancer risks increase from the thirties onward
• Sex: Affects both sexes equally, though cancer types differ — breast and endometrial cancer primarily affect women

The skin is the most consistently affected organ, with over 99% of patients developing mucocutaneous lesions by their late twenties. These lesions are benign but serve as critical diagnostic clues.

• Trichilemmomas: Small (1–5 mm), skin-coloured or slightly yellowish papules on the face, especially around the nose, mouth, and ears — the most characteristic skin finding
• Oral papillomas: Small papules on the lips, gums, and inner cheeks that can merge into a cobblestone pattern; may also give the tongue a furrowed (scrotal) appearance
• Acral keratoses: Flat-topped, wart-like papules (1–4 mm) on the backs of the hands and feet
• Palmoplantar keratoses: Translucent, hard papules on the palms and soles, sometimes with a central pit
• Macrocephaly: An abnormally large head circumference, present in most patients (85–100% of children with PHTS)
• Lipomas: Benign fatty tumours under the skin; present in approximately 35–57% of patients

Other features may include penile freckling in males (19–54%), vascular malformations, and gastrointestinal polyps.

Cowden syndrome is caused by mutations in the PTEN gene, located on chromosome 10.

• PTEN function: PTEN is a tumour suppressor gene — it produces a protein that regulates cell growth and division. When PTEN is mutated, cells can grow and divide in an uncontrolled manner
• Inheritance pattern: Autosomal dominant with variable expressivity — family members carrying the same mutation may develop very different manifestations
• Penetrance: Nearly complete for mucocutaneous features (>99% by age 30), but variable for cancer
• PTEN-negative cases: Approximately 25–35% of patients who meet clinical diagnostic criteria do not have a detectable PTEN mutation; other genes may be involved

Diagnosis is based on clinical criteria combined with genetic testing.

• Clinical assessment: Recognition of multiple mucocutaneous lesions (trichilemmomas, oral papillomas, acral keratoses) combined with macrocephaly and/or a personal or family history of characteristic cancers
• Revised diagnostic criteria (NCCN): Major criteria include breast cancer, thyroid carcinoma (especially follicular), endometrial cancer, macrocephaly, Lhermitte-Duclos disease (cerebellar hamartoma), and multiple mucocutaneous lesions. Minor criteria include colorectal cancer, renal cell carcinoma, lipomas (≥3), autism spectrum disorder, and vascular anomalies
• Genetic testing: PTEN gene sequencing confirms the diagnosis; recommended for all patients meeting clinical criteria and for at-risk family members
• Skin biopsy: Histopathology of trichilemmomas shows a characteristic lobular proliferation of clear cells with peripheral palisading on a thickened basement membrane
• Dermoscopy: Trichilemmomas show a radiated red iris-like structure

There is no cure for Cowden syndrome. Management focuses on cancer surveillance and treatment of symptomatic lesions.

Cancer surveillance (lifelong):

• Breast: Annual breast MRI from age 25; mammography added from age 40. Discussion of risk-reducing mastectomy from age 25
• Thyroid: Baseline thyroid ultrasound from age 12; repeated every 3–5 years (or every 2–3 years if nodules are found)
• Colon: Baseline colonoscopy at age 35–40
• Endometrium: Education about abnormal bleeding from age 30–35
• Kidney: Consider renal ultrasound every 2 years from age 35–40

Skin lesion management:

• Trichilemmomas are benign and do not require treatment unless cosmetically bothersome — can be removed by excision, laser (CO₂), or electrosurgery
• Oral papillomas may be treated with topical retinoids, though they tend to recur after stopping treatment
• Acral and palmoplantar keratoses can be treated with topical keratolytics or cryotherapy

Emerging therapies:

• mTOR inhibitors (sirolimus) have shown improvement in mucocutaneous lesions in pilot studies

• Cowden syndrome is a lifelong condition that requires ongoing cancer surveillance — early detection is the best protection
• The mucocutaneous lesions (skin growths, oral papules, hand keratoses) are benign and not dangerous in themselves, but they are important warning signs that should prompt genetic evaluation
• When to seek medical attention: A family history of multiple cancers (especially breast, thyroid, uterine) combined with skin papules or a large head circumference; any new lumps, unusual bleeding, or persistent symptoms
• Genetic counselling is recommended for all affected individuals and at-risk family members — each child of an affected parent has a 50% chance of inheriting the condition
• Cowden syndrome is likely underdiagnosed — if you recognise these features in yourself or a family member, consult a dermatologist or geneticist

• Prevalence: ~1:200,000 (Pirlog et al., 2024); likely underestimated due to variable expressivity and underrecognition
• Inheritance: Autosomal dominant; 60–90% of pathogenic variants are inherited (Magana et al., 2022); de novo mutations account for the remainder
• Demographics: Equal sex distribution; median age at diagnosis ~36 years (Hendricks et al., 2021). Mucocutaneous lesions typically manifest in the 2nd–3rd decade, predating malignancies
• PHTS spectrum: Cowden syndrome is the most commonly diagnosed PHTS phenotype; the spectrum also includes Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome, and autism spectrum disorder with macrocephaly

Genetics

• PTEN (phosphatase and tensin homolog): Tumour suppressor gene on chromosome 10q23, encoding a dual-specificity phosphatase (Nelen et al., 1996)
• Functions as a lipid phosphatase: dephosphorylates PIP3, antagonising the PI3K/AKT/mTOR pathway — the master regulator of cell growth, proliferation, and survival
• Loss of PTEN function → constitutive activation of PI3K/AKT/mTOR → uncontrolled cell proliferation and hamartoma formation
• PTEN mutation rate in clinically diagnosed CS: ~25–35% when using broad clinical criteria (Pilarski, 2019); 80–95% in well-characterised cohorts with strict criteria
• Saturation mutagenesis identified 2,273 PTEN variants with reduced lipid phosphatase activity (Mighell et al., 2018)
• ~50% of patients meeting CS clinical criteria are PTEN-wildtype; 8% harbour pathogenic variants in other cancer susceptibility genes (BRCA1/2, TSC2, RET, HRAS) (Yehia et al., 2018)

Genotype-phenotype correlations

• C2 domain variants associated with significantly higher cancer incidence (Teramae et al., 2022)
• All females with C2 domain variants developed breast cancer in a Japanese cohort
• ASD-associated mutations tend to be hypomorphic (partial loss of function) vs. complete loss-of-function mutations in classic PHTS cancer phenotypes (Mighell et al., 2018)

Mucocutaneous features (>99% by age 30)

Trichilemmomas (pathognomonic):

• Benign hamartomas of the outer root sheath of hair follicles
• 1–5 mm skin-coloured to yellowish papules, predominantly on face (perinasal, perioral, periauricular)
• Prevalence: 6–38% in PTEN-confirmed patients (Lim & Ngeow, 2021)
• Histopathology: folliculocentric lobular proliferation of clear (glycogen-rich, PAS-positive) isthmic cells with peripheral nuclear palisading on a thickened hyaline basement membrane
• Dermoscopy: radiated red iris-like structure

Oral mucosal papillomas:

• 1–3 mm papules coalescing into cobblestone pattern
• Lips, buccal mucosae, gingivae; scrotal tongue appearance
• Prevalence: 15–85% in PTEN-confirmed patients

Acral keratoses:

• Flat-topped, wart-like papules 1–4 mm on dorsum of hands and feet
• Prevalence: 10–82% (wide range reflects ascertainment variability)

Palmoplantar keratoses:

• Translucent hard papules ± central pit
• Punctate keratoses resembling arsenical keratoses

Other cutaneous features:

• Penile macular pigmentation (major criterion): 19–54% of PTEN-confirmed males; earliest report at 15 months
• Lipomas: 35–57%; ≥3 required for minor criterion
• Mucocutaneous neuromas: 5–11%, painful dome-shaped translucent papules
• Vascular anomalies: haemangiomas (~22%), arteriovenous malformations (6–11%)

Non-cutaneous features

• Macrocephaly: 85–100% of pediatric PHTS patients; often the earliest clinical sign
• Gastrointestinal: Hamartomatous polyps throughout GI tract (54% of patients; Schei-Andersen et al., 2025); esophageal glycogenic acanthosis
• Thyroid: Multinodular goitre, follicular adenoma, Hashimoto thyroiditis
• Breast: Fibrocystic disease, fibroadenomas
• Neurological: Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma); autism spectrum disorder (~25–27%); developmental delay (42% in pediatric cohorts)
• Genitourinary: Uterine fibroids, uterine polyps; testicular lipomatosis

Cancer risks (cumulative lifetime)

Cancer	Lifetime risk	General population risk
Breast (female)	67–91%	~13%
Thyroid (follicular >> papillary)	17–38%	~1%
Endometrial	19–48%	~3%
Colorectal	9–32%	~4%
Renal cell carcinoma	10–30%	~2%
Melanoma	0–6%	~2%
Any cancer (female)	73–90%	—
Any cancer (overall)	81–90%	—

• Second primary cancer risk (10-year): 45.7% in females, 19.8% in males (Hendricks et al., 2025)
• 10-year risk of second primary breast cancer after first: 45.6%

Revised NCCN clinical diagnostic criteria (Pilarski et al., 2013)

Major criteria:

• Breast cancer
• Epithelial thyroid cancer (especially follicular)
• Endometrial cancer
• Macrocephaly (≥97th percentile)
• Lhermitte-Duclos disease (adult)
• Multiple mucocutaneous lesions (≥3 trichilemmomas, ≥3 oral papillomas, or ≥6 facial papules of which ≥3 are trichilemmomas)
• Penile freckling

Minor criteria:

• Colorectal cancer
• Renal cell carcinoma
• Esophageal glycogenic acanthosis (≥3)
• Lipomas (≥3)
• Autism spectrum disorder
• Testicular lipomatosis
• Vascular anomalies (including multiple intracranial developmental venous anomalies)

Operational diagnosis (individual without family history):

• ≥3 major criteria (must include macrocephaly or mucocutaneous lesions), OR
• 2 major criteria + ≥3 minor criteria

Operational diagnosis (individual with family history of CS/BRRS/PHTS):

• ≥2 major criteria (with or without minor), OR
• 1 major + ≥2 minor criteria, OR
• ≥3 minor criteria

Genetic testing

• PTEN sequencing and deletion/duplication analysis
• Recommended for all patients meeting clinical criteria
• Cascade testing for at-risk family members
• Consider multigene panel if PTEN-negative (to evaluate BRCA1/2, TSC2, etc.)

Trichilemmoma:

• Well-circumscribed lobular proliferation of pale/clear glycogen-rich cells
• PAS-positive, diastase-sensitive cytoplasm
• Peripheral nuclear palisading
• Thickened hyaline (vitreous) basement membrane surrounding lobules
• Folliculocentric growth pattern

Desmoplastic trichilemmoma (variant):

• Central sclerotic stroma with compressed epithelial strands
• Can mimic invasive carcinoma; PTEN immunohistochemistry helpful (loss of expression)

Condition	Key distinguishing features
Bannayan-Riley-Ruvalcaba syndrome	Macrocephaly, lipomas, hamartomatous polyps, penile freckling; also PTEN-mutated; part of PHTS spectrum — same gene, overlapping phenotype
Birt-Hogg-Dubé syndrome	Fibrofolliculomas (not trichilemmomas), lung cysts, spontaneous pneumothorax, renal tumours; FLCN gene
Muir-Torre syndrome	Sebaceous neoplasms + visceral malignancies; mismatch repair gene mutations (Lynch spectrum)
Multiple endocrine neoplasia type 1	Facial angiofibromas, collagenomas; parathyroid/pituitary/pancreatic tumours; MEN1 gene
Tuberous sclerosis complex	Facial angiofibromas, periungual fibromas, shagreen patches, ash-leaf macules; TSC1/TSC2 genes
Peutz-Jeghers syndrome	Mucocutaneous pigmentation (lips, buccal), hamartomatous polyps; STK11 gene
Juvenile polyposis syndrome	Hamartomatous polyps without mucocutaneous features; SMAD4/BMPR1A genes
Verruca vulgaris	Sporadic warts; HPV-positive; no systemic associations

Cancer surveillance (International PHTS Consensus Guidelines, Dhawan et al., 2025)

Breast (females):

• Clinical breast exam every 6–12 months from age 25
• Annual breast MRI from age 25 (strong evidence)
• Annual mammography from age 40 (strong evidence)
• Discuss risk-reducing mastectomy from age 25 (moderate evidence)
• MRI sensitivity 100% vs. mammography 50% (Hoxhaj et al., 2022)

Thyroid:

• Baseline thyroid ultrasound from age 12
• Repeat every 3–5 years if no nodules; every 2–3 years if nonactionable nodules (moderate evidence)
• Annual neck palpation in children from age 10
• No routine risk-reducing thyroidectomy recommended
• Follicular thyroid carcinoma overrepresented in PHTS (52% of pediatric thyroid cancers)

Colon:

• Baseline colonoscopy at age 35–40 (moderate evidence)
• Frequency guided by findings

Endometrium:

• Education about abnormal bleeding at diagnosis or age 30–35 (weak evidence)
• No routine surveillance recommended outside clinical trials
• Risk-reducing hysterectomy may be discussed after childbearing

Kidney:

• Consider renal ultrasound every 2 years from age 35–40 (expert opinion)

Dermatological:

• Annual comprehensive skin examination
• Low threshold for biopsy of suspicious lesions (melanoma risk 0–6%)

Management of mucocutaneous lesions

• Trichilemmomas: benign; excision, CO₂ laser, or electrosurgery for cosmetic concerns
• Oral papillomas: topical retinoids (partial response; recurrence after cessation); surgical removal if symptomatic
• Acral/palmoplantar keratoses: topical keratolytics (salicylic acid, urea), cryotherapy
• Lipomas: excision if symptomatic

Emerging targeted therapies

• mTOR inhibitors (sirolimus/rapamycin): Rationale — PTEN loss → constitutive mTOR activation. Pilot study of 18 patients showed improvement in mucocutaneous lesions (Lim & Ngeow, 2021). Further trials needed.
• PTEN loss as a biomarker for PI3K/AKT/mTOR pathway inhibitors in PHTS-related cancers

Pediatric PHTS

• Macrocephaly is often the earliest sign (present in 85–100%)
• ASD prevalence ~25–27%; developmental delay 42% (Baran et al., 2021)
• Skin/oral lesions present in ~31% of pediatric patients
• Thyroid cancer: 4–12% incidence in childhood; youngest reported at age 4; follicular predominance
• Thyroid surveillance from age 10–12 (Jonker et al., 2020)
• Neurodevelopmental screening recommended at diagnosis

Pregnancy

• Standard-of-care cancer management; no increased secondary malignancy risk from chemotherapy/radiotherapy (Dhawan et al., 2025)
• Pre-implantation genetic testing or prenatal diagnosis available

• Mucocutaneous features: Lifelong; benign but progressive
• Cancer risk: Markedly elevated lifetime risk; early detection through surveillance is critical
• With surveillance: Surveillance-detected breast cancers: all T1/N0 (early stage); outside-surveillance: ≥T2 (60%), node-positive (45%) (Hoxhaj et al., 2022)
• Second primary cancers: Very high risk, especially in females (45.7% at 10 years)
• Quality of life: Psychological impact of lifelong cancer surveillance and uncertainty; genetic counselling essential

• Trichilemmomas are the pathognomonic cutaneous marker — if you see multiple facial papules in a young adult, especially perinasal, think Cowden syndrome
• Macrocephaly is the earliest and most consistent sign in children — measure head circumference in any child with developmental delay and skin lesions
• Not all Cowden syndrome is PTEN-mutated — ~25–35% of clinically diagnosed patients are PTEN-wildtype; consider multigene panel testing
• Follicular thyroid carcinoma is overrepresented in PHTS — a follicular thyroid cancer in a young patient should prompt evaluation for CS
• The cobblestone oral mucosa and scrotal tongue are distinctive — always examine the oral cavity
• Breast MRI, not mammography, is the primary screening tool from age 25 — mammography alone misses 50% of cancers
• Risk-reducing mastectomy discussion should begin at age 25, not deferred until cancer occurs
• Penile freckling is a major criterion and often overlooked — examine in male patients
• CS is a clinical diagnosis with genetic confirmation — a negative PTEN test does not exclude the diagnosis if clinical criteria are met